PHP
MBX

Parkman Healthcare Partners’s MBX Biosciences MBX Stock Holding History

Parkman Healthcare Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2M Buy
800,173
+136
+0% +$4.75K 4.52% 1
2026
Q1 		$23.9M Sell
800,037
-85,602
-10% -$2.91M 2.46% 13
2025
Q4 		$27.9M Buy
885,639
+112,335
+15% +$2.73M 2.66% 8
2025
Q3 		$13.5M Sell
773,304
-98,629
-11% -$1.32M 1.41% 22
2025
Q2 		$9.95M Buy
871,933
+543,610
+166% +$5.54M 1.14% 29
2025
Q1 		$2.42M Buy
328,323
+158,323
+93% +$1.67M 0.29% 71
2024
Q4 		$3.13M Buy
+170,000
New +$3.62M 0.42% 60

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Parkman Healthcare Partners's MBX Position: Q2 2026 in Review

Parkman Healthcare Partners increased its MBX Biosciences (MBX) stake by 0.02% in Q2 2026, buying an estimated $4.75K and bringing the position to 800,173 shares worth $44.2M. The position accounts for 4.52% of the portfolio, ranked #1.

Parkman Healthcare Partners first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Parkman Healthcare Partners held 800,173 shares of MBX Biosciences worth $44.2M as of Q2 2026.
  • Parkman Healthcare Partners bought 136 MBX Biosciences shares in Q2 2026, an estimated $4.75K.
  • MBX Biosciences made up 4.52% of Parkman Healthcare Partners's portfolio in Q2 2026, its #1 holding.
  • Parkman Healthcare Partners first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.